Erlangga, Z.; Wolff, K.; Poth, T.; Peltzer, A.; Nahnsen, S.; Spielberg, S.; Timrott, K.; Woller, N.; Kühnel, F.; Manns, M.P.;
et al. Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. Cancers 2019, 11, 1904.
https://doi.org/10.3390/cancers11121904
AMA Style
Erlangga Z, Wolff K, Poth T, Peltzer A, Nahnsen S, Spielberg S, Timrott K, Woller N, Kühnel F, Manns MP,
et al. Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. Cancers. 2019; 11(12):1904.
https://doi.org/10.3390/cancers11121904
Chicago/Turabian Style
Erlangga, Zulrahman, Katharina Wolff, Tanja Poth, Alexander Peltzer, Sven Nahnsen, Steffi Spielberg, Kai Timrott, Norman Woller, Florian Kühnel, Michael P. Manns,
and et al. 2019. "Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer" Cancers 11, no. 12: 1904.
https://doi.org/10.3390/cancers11121904
APA Style
Erlangga, Z., Wolff, K., Poth, T., Peltzer, A., Nahnsen, S., Spielberg, S., Timrott, K., Woller, N., Kühnel, F., Manns, M. P., Saborowski, A., Vogel, A., & Saborowski, M.
(2019). Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. Cancers, 11(12), 1904.
https://doi.org/10.3390/cancers11121904